2026 AUA Vasectomy Guideline: Key updates and clinical FAQs

The American Urological Association has published their 2026 Vasectomy Guideline,^1,2 reflecting approximately a decade of new evidence and evolving clinical practice. According to guideline vice chair Akanksha Mehta, MD, MS, this guideline represents a comprehensive overhaul of prior recommendations, with a key distinguishing feature being its broadened scope.

“There was about a 10-year time period between the new guidelines and the old guidelines. So, this represents a completely new set of guidelines,” she explained. “The additional charge for our committee this time around was not just to focus on the procedure of vasectomy, but also to discuss fertility options for men who had undergone prior vasectomy [and are] interested in future fertility.”

Clinically, the guideline reinforces several core principles: vasectomy remains a safe and effective form of permanent contraception; there is no causal association with systemic diseases such as prostate cancer or cardiovascular conditions; and optimizing procedural technique—particularly through mucosal cautery and fascial interposition—can minimize failure rates. Additionally, evolving approaches to post-vasectomy semen analysis (PVSA), including mail-in testing, reflect an effort to improve patient adherence and streamline follow-up.

According to Mehta, the 2 key takeaways are the importance of patient counseling and how rapidly testing for post-vasectomy success is changing. In the following FAQ, we highlight key guideline recommendations relevant to urologists.

Frequently Asked Questions

1. What should clinicians emphasize during pre-operative counseling?

Clinicians should counsel that vasectomy is a safe, effective, and intended permanent method of contraception. According to Mehta, counseling should be individualized and centered on the patient’s reproductive goals. This consultation can be provided either in person or virtually.

Importantly, clinicians should address misconceptions about long-term health risks. As Mehta noted, “There is no evidence for causation. Just because somebody has a vasectomy does not mean that they are more likely to develop low testosterone, prostate cancer, stone disease, or cardiovascular disease later in life. They may naturally develop any of those things based on their other health risk factors, but it's not associated with the vasectomy.”

2. Is there a link between vasectomy and prostate cancer or other systemic diseases?

No causal association has been established between vasectomy and prostate cancer, high-grade prostate cancer, prostate cancer mortality, nor with cardiovascular disease or nephrolithiasis. The guideline supports counseling patients that these risks are not increased due to vasectomy.

3. Are peri-procedural antibiotics recommended?

Routine antibiotic prophylaxis is not recommended for uncomplicated vasectomy. Antibiotics may be considered in select high-risk patients (e.g., those with infection risk factors).

4. What is the recommended anesthesia approach?

Vasectomy should be performed using local anesthesia delivered via skin infiltration with a needle or jet injector. Topical anesthetics may be used to reduce discomfort during infiltration.

5. What vas isolation technique is preferred?

A minimally invasive approach—such as the no-scalpel vasectomy (NSV) technique—is recommended for vas isolation.

6. What occlusion technique is recommended?

The guideline strongly recommends combining mucosal cautery (MC) with fascial interposition (FI).

As Mehta explained, “if a urologist is able to do both of those things, then they are in the lowest category for risk of vasectomy failure.” Use of ligation and excision of a short vas segment alone is discouraged due to higher failure rates.

7. Is histologic evaluation of excised tissues necessary?

No. Routine histologic evaluation of excised vas segments is not required, as it does not impact clinical outcomes.

8. What are the key complications clinicians should monitor for?

Clinicians should be prepared to recognize and manage complications including bleeding, infection, epididymitis, and chronic scrotal pain.

9. What are the current recommendations for post-vasectomy semen analysis (PVSA)?

Patients should provide at least 1 semen sample to confirm occlusive success. Patients may discontinue contraception following confirmation of complete azoospermia or ≤100,000 rare non-motile sperm per mL in an uncentrifuged sample evaluated within 2 hours of collection. For samples evaluated more than 2 hours after collection, confirmation of complete azoospermia is needed to stop contraception.

As Mehta highlighted, “you only need one semen analysis…you do not need to repeat analyzes at all” if these criteria are met.

10. When should PVSA be performed?

PVSA may be performed as early as 8 weeks post-procedure, with many clinicians targeting approximately 8–10 weeks to balance accuracy and patient convenience.

11. How should persistent sperm be managed after vasectomy?

If motile sperm persist, repeat testing is required. For persistent motile sperm at 6 months, clinicians should counsel patients regarding repeat vasectomy.

Mehta noted, “If you've had 6 months of waiting time and the patient has complied with the recommendations for ejaculation before submitting their sample, and you're still seeing motile sperm of any quantity, rare or not rare, then that probably warrants discussion about a redo vasectomy. Technically that patient is not sterile, and the risk of them having an unintended pregnancy is not insignificant.”

For persistent non-motile sperm greater than 100,000/mL, shared decision-making should guide next steps (repeat vasectomy, continue contraception, and/or obtain repeat semen evaluations).

12. What role do mail-in semen analysis tests play?

Mail-in PVSA tests are an acceptable option and may improve patient adherence. However, Mehta noted that these tests require azoospermia to confirm success; any detected sperm is considered a failed result due to assay limitations.

13. What should clinicians discuss regarding future fertility?

Patients should be counseled that fertility restoration is possible but not guaranteed. Options include vasectomy reversal and sperm retrieval with intracytoplasmic sperm injection. According to the guideline, “Surgeons offered vasectomy reversal should have microsurgical expertise to provide vasoepididymostomy as well as vasovasostomy.”

Mehta emphasized that these options involve additional cost, time, and complexity, reinforcing that vasectomy should still be considered a permanent contraceptive method.

Surgeons should also counsel patients that the best preoperative predictors of post-operative reversal success are duration of the obstructive interval, patient age, and female partner age.

REFERENCES

1. Schlegel PN, Clark JY, Coward , RM, et al. Vasectomy: AUA Guideline Part I. J Urol. 0(0). doi:10.1097/JU.0000000000004861. https://www.auajournals.org/doi/10.1097/JU.0000000000004861

2. Schlegel PN, Clark JY, Coward , RM, et al. Fertility Restoration After Vasectomy: AUA Guideline Part II. J Urol. 0(0). doi:10.1097/JU.0000000000004862. https://www.auajournals.org/doi/10.1097/JU.0000000000004862